These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26740054)

  • 41. Elevated Choline Kinase α-Mediated Choline Metabolism Supports the Prolonged Survival of TRAF3-Deficient B Lymphocytes.
    Gokhale S; Lu W; Zhu S; Liu Y; Hart RP; Rabinowitz JD; Xie P
    J Immunol; 2020 Jan; 204(2):459-471. PubMed ID: 31826940
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma.
    Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW
    Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling.
    Accardi F; Toscani D; Bolzoni M; Dalla Palma B; Aversa F; Giuliani N
    Biomed Res Int; 2015; 2015():172458. PubMed ID: 26579531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
    Mitsiades N; Mitsiades CS; Poulaki V; Chauhan D; Fanourakis G; Gu X; Bailey C; Joseph M; Libermann TA; Treon SP; Munshi NC; Richardson PG; Hideshima T; Anderson KC
    Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14374-9. PubMed ID: 12391322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.
    Luo H; Feng Y; Wang F; Lin Z; Huang J; Li Q; Wang X; Liu X; Zhai X; Gao Q; Li L; Zhang Y; Wen J; Zhang L; Niu T; Zheng Y
    Cancer Lett; 2023 Jul; 565():216218. PubMed ID: 37149018
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
    Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
    Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination of SAHA and bortezomib up-regulates CDKN2A and CDKN1A and induces apoptosis of Epstein-Barr virus-positive Wp-restricted Burkitt lymphoma and lymphoblastoid cell lines.
    Hui KF; Leung YY; Yeung PL; Middeldorp JM; Chiang AK
    Br J Haematol; 2014 Dec; 167(5):639-50. PubMed ID: 25155625
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dysregulated TRAF3 and BCL2 Expression Promotes Multiple Classes of Mature Non-hodgkin B Cell Lymphoma in Mice.
    Perez-Chacon G; Adrados M; Vallejo-Cremades MT; Lefebvre S; Reed JC; Zapata JM
    Front Immunol; 2018; 9():3114. PubMed ID: 30687320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
    Shringarpure R; Catley L; Bhole D; Burger R; Podar K; Tai YT; Kessler B; Galardy P; Ploegh H; Tassone P; Hideshima T; Mitsiades C; Munshi NC; Chauhan D; Anderson KC
    Br J Haematol; 2006 Jul; 134(2):145-56. PubMed ID: 16846475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.
    Zaman S; Shentu S; Yang J; He J; Orlowski RZ; Stellrecht CM; Gandhi V
    Neoplasia; 2015 Mar; 17(3):289-300. PubMed ID: 25810013
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.
    Cosenza M; Civallero M; Pozzi S; Marcheselli L; Bari A; Sacchi S
    Hematol Oncol; 2015 Dec; 33(4):166-75. PubMed ID: 25394177
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
    Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
    Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection.
    Iwata S; Yano S; Ito Y; Ushijima Y; Gotoh K; Kawada J; Fujiwara S; Sugimoto K; Isobe Y; Nishiyama Y; Kimura H
    Int J Cancer; 2011 Nov; 129(9):2263-73. PubMed ID: 21170988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
    Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
    Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The adaptor protein TRAF3 inhibits interleukin-6 receptor signaling in B cells to limit plasma cell development.
    Lin WW; Yi Z; Stunz LL; Maine CJ; Sherman LA; Bishop GA
    Sci Signal; 2015 Sep; 8(392):ra88. PubMed ID: 26329582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.
    Khalesi N; Korani S; Korani M; Johnston TP; Sahebkar A
    Inflammopharmacology; 2021 Oct; 29(5):1291-1306. PubMed ID: 34424482
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.
    Bushell KR; Kim Y; Chan FC; Ben-Neriah S; Jenks A; Alcaide M; Fornika D; Grande BM; Arthur S; Gascoyne RD; Steidl C; Morin RD
    Blood; 2015 Feb; 125(6):999-1005. PubMed ID: 25468570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.